Arturo Prida Romero – President, IX National Council del Partido de la…
Arturo Prida Romero, the president of the current National Council of the Partido de la Revolución Democrática (PRD) – one of the main political parties in Mexico – shares the…
The National Institute of Psychiatry Ramón de la Fuente is a decentralized public institution part of the system of National Institutes of Health in Mexico. Founded in 1976 the functions of the Institute are: to conduct scientific research, to instruct qualified personnel to conduct these investigations, to train professionals and technicians in these fields, to treat psychiatric patients and to act as an advisor to other official and private organisms. The Institute participates in the development of health policies by coordinating with institutions at national level with both the government and civil society, by helping in the adoption of new policies in the areas of mental health and substance abuse in its role as member of the National Council against Addictions and organism in charge of mental health in the country. Since 1976 the Institute has been designated as a WHO/PAHO Collaborating Centre and been continuously re-designated every four years until 2015. The Institute possesses three research branches― neuroscience, clinical, epidemiological, and psychosocial research — an education office and an area of clinical services.
Arturo Prida Romero, the president of the current National Council of the Partido de la Revolución Democrática (PRD) – one of the main political parties in Mexico – shares the…
Mario Muniz, SVP and GM of IQVIA North LATAM, shares his motivations for joining IQVIA after nearly two decades with pharma and medtech companies, the huge potential of the North…
Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key…
Diego Ruiz, CEO and co-founder of Eseotr3s Pharma shares his entrepreneurial background and the motivation for establishing Eseotr3s Pharma; their focus on flexibility and quality; their international operations and network,…
Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico.…
Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global reshuffle has impacted Mexican operations, and the challenges inherent in bringing…
David López García, Mexico country manager of global rare genetic therapy player Biomarin, outlines the challenging situation around patient access to orphan drugs in Mexico and the importance of building…
Dr David Kershenobich Stalnikowitz, director-general of the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ) shares the many new initiatives the Institute has introduced in the past couple…
In the historic year of their 70th anniversary, Cristóbal Thompson, executive director of the Asociación Mexicana de Industrias de Investigación Farmacéutica (AMIIF), the association for research-based pharmaceutical companies in Mexico,…
Rafael Gual Cosío, director general of the Cámara Nacional de la Industria Farmacéutica (CANIFARMA), the umbrella industry association for the healthcare sector in Mexico, shares his perspectives on the complex…
The election of populist President Andres Manuel Lopez Obrador (AMLO) on 1 July 2018 heralded a new era of hope and optimism for Mexicans. In the first 13 months of…
Juan de Villafranca, executive director of the Asociacion Mexicana de Laboratorios Farmaceuticos (AMELAF), shares the exciting new initiatives he has launched in the past two years of his term; the…
See our Cookie Privacy Policy Here
